SL-901
- Generic Name
- SL-901
Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05382936
- Locations
- 🇬🇧
Royal Marsden Hospital, Sutton, Surrey, United Kingdom
🇬🇧Christie Hospital, Manchester, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath